Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
2-CHLOROETHYL-3-SARCOSINAMIDE-1-NITROSOUREA NOVEL CHLOROETHYLNITROSOUREA ANALOG WITH ENHANCED ANTITUMOR-ACTIVITY AGAINST HUMAN GLIOMA XENOGRAFTS
Autore:
MARCANTONIO D; PANASCI LC; HOLLINGSHEAD MG; ALLEY MC; CAMALIER RF; SAUSVILLE EA; DYKES DJ; CARTER CA; MALSPEIS L;
Indirizzi:
SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,3755 COTE STE CATHERINE MONTREAL PQ H3T 1E2 CANADA SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES MONTREAL PQ H3T 1E2 CANADA FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT DIAG & CTR,DEV THERAPEUT PROGRAM FREDERICK MD 21701 SO RES INST BIRMINGHAM AL 35205
Titolo Testata:
Cancer research
fascicolo: 18, volume: 57, anno: 1997,
pagine: 3895 - 3898
SICI:
0008-5472(1997)57:18<3895:2NC>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
AMINO-ACID AMIDES; CLINICAL-TRIAL; (2-CHLOROETHYL)-3-SARCOSINAMIDE-1-NITROSOUREA; RADIOTHERAPY; CYTOTOXICITY; CONGENERS; TRANSPORT; SK-MG-1; CARRIER; SYSTEM;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
18
Recensione:
Indirizzi per estratti:
Citazione:
D. Marcantonio et al., "2-CHLOROETHYL-3-SARCOSINAMIDE-1-NITROSOUREA NOVEL CHLOROETHYLNITROSOUREA ANALOG WITH ENHANCED ANTITUMOR-ACTIVITY AGAINST HUMAN GLIOMA XENOGRAFTS", Cancer research, 57(18), 1997, pp. 3895-3898

Abstract

Nitrosoureas are among the most widely used agents used in the treatment of malignant gliomas, Here, the activity of 2-chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) was compared with that of 1,3-bis-(2-chloroethyl) -1-nitrosourea (BCNU), in vivo against s.c. implanted SF-295 and U-251 central nervous system (CNS) tumor xenografts. When given i.v., q4d for 3 doses, to athymic mice bearing s.c. SF-295 tumors, SarCNU, at an optimum of 167 mg/kg/dose, produced 9 tumor-free animals of10 total animals, 1 regression, and no evidence of overt toxicity (greater than or equal to 20% body weight loss). With a similar dosing schedule, BCNU produced no tumor-free animals, six regressions, and one drug-related death at its optimum of 30 mg/kg/dose. Furthermore, SarCNU retained high antitumor activity at two lower dose levels, 66 and 45% of the optimal dose, whereas BCNU demonstrated a progressive loss ofantitumor activity at lower doses. Following p.o. administration, SarCNU similarly demonstrated antitumor activity that was superior to that of BCNU, In the U-251 CNS tumor model, SarCNU yielded six of six tumor-free animals at 80 mg/kg/dose with i.p. administration q.d. for 5 days, starting on day 14, whereas BCNU, at 9 mg/kg/dose, yielded three of six tumor-free mice and one drug-related death. Again, SarCNU resulted in tumor-free animals at 66 and 45% of its optimal dose and was relatively nontoxic, in contrast to BCNU. Results of testing to date indicate that SarCNU is clearly more effective than BCNU against the human CNS tumors SF-295 and U-251 lit vivo. These results encourage the initiation of clinical trials for SarCNU, in an effort to improve therapeutic approaches to glioma, but clinical trials must determine whethersuperiority of SarCNU in preclinical models can be extrapolated to patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 18:27:34